Literature DB >> 27556795

Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone.

Sophie Bourgeois1, Pieterjan Gykiere, Lode Goethals, Hendrik Everaert, Frank W De Geeter.   

Abstract

Ga-PSMA plays an increasing role in prostate cancer management, but several instances of false positivity have now been recognized. We present a patient with metastatic prostatic carcinoma who also showed overexpression of PSMA in Paget disease of the humerus on Ga-PSMA PET. This probably relates to bone remodeling and increased vascularity. It is important to be aware of this aspecific uptake because its recognition may avoid overstaging and may alter the therapeutic choice.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27556795     DOI： 10.1097/RLU.0000000000001335

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  11 in total

1.  [68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer.

Authors:  Nader Hirmas; Akram Al-Ibraheem; Ken Herrmann; Abedalatif Alsharif; Haider Muhsin; Jamal Khader; Ali Al-Daghmin; Samer Salah
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

2.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

3.  Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers.

Authors:  Nishikant Avinash Damle; Chandrasekhar Bal; Tejesh Pratap Singh; Ravikant Gupta; Sreenivasa Reddy; Rajeev Kumar; Madhavi Tripathi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-02       Impact factor: 9.236

4.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 5.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 6.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

7.  Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block.

Authors:  Ansje S Fortuin; Roger Brüggemann; Janine van der Linden; Ilia Panfilov; Bas Israël; Tom W J Scheenen; Jelle O Barentsz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-04-06

8.  PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings.

Authors:  Michael Froehner; Marieta Toma; Klaus Zöphel; Vladimir Novotny; Michael Laniado; Manfred P Wirth
Journal:  Case Rep Urol       Date:  2017-03-15

9.  Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?

Authors:  Saurabh Arora; Meghana Prabhu; Nishikant Avinash Damle; Chandrasekhar Bal; Praveen Kumar; Harish Nalla; Sreedharan Thankarajan Arun Raj
Journal:  Indian J Nucl Med       Date:  2018 Jul-Sep

10.  Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer.

Authors:  Sarah Piron; Kathia De Man; Vanessa Schelfhout; Nick Van Laeken; Ken Kersemans; Eric Achten; Filip De Vos; Piet Ost
Journal:  EJNMMI Res       Date:  2020-02-24       Impact factor: 3.138
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.